Navigation Links
Topiramate Exposure and Birth Defect Data to be Presented at the 29th International Epilepsy Congress
Date:7/20/2011

A(3)Columbia Comprehensive Epilepsy Center, New York, United States, (2)Emory University, Atlanta, United States, (3)Wolters Kluwer Pharma Solutions, Yardley, United States
Poster Session: Late Submissions
Poster #: 866
Time: 1:00-2:30 local time

About QNEXA Controlled Release CapsulesQNEXA [kyoo-nek-suh] is an investigational drug candidate being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. QNEXA is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which is designed to decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase 2 and 3 clinical data to date, patients taking QNEXA have demonstrated statistically significant weight loss, glycemic control, and improvement in cardiovascular risk factors, when used in combination with a diet and lifestyle modification program.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use o
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
2. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
3. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
4. Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate
5. FDA: Risk of Oral Birth Defects in Children Born to Mothers Taking Topiramate
6. Phase I Research of Extended-Release Topiramate Shows Less Fluctuation in Plasma Levels
7. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
8. Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
9. HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference
10. New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option
11. Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 2015 Research and Markets ... "Diabetes Care Devices Market In Brazil, Russia, India ... Continuous Glucose Monitors, Testing Strips, Lancets, Insulin Pumps, Insulin ... to their offering. The BRIC diabetes care ... 1.7 Billion in 2015 and is poised to reach ...
(Date:9/3/2015)... 2015  VirtualScopics, Inc. (NASDAQ: VSCP ), ... announced today, they are collaborating with a large ... epidemiology study partnering with the Ministry of Health ... teamed up with a cardiac sonographer to acquire ... will be used to identify children with rheumatic ...
(Date:9/3/2015)... YORK , Sept. 3, 2015  The findings ... are raising disturbing questions about the company,s handling of ... LLP reports.  On September 2 nd , part ... 300 adverse events, including at least 27 fatalities, have ... disclosed a confidential study commissioned by C.R. Bard in ...
Breaking Medicine Technology:The BRIC Diabetes Care Devices Market is Estimated to Grow at a CAGR of 6.3% from 2015 to 2020, to Reach USD 2.3 Billion by 2020 2The BRIC Diabetes Care Devices Market is Estimated to Grow at a CAGR of 6.3% from 2015 to 2020, to Reach USD 2.3 Billion by 2020 3VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 2VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 3VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 4IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 2IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 3
... , MADISON, N.J., Nov. 2 Quest Diagnostics Incorporated ... diagnostic testing, information and services, announced that it is ... Conference in New York City. The presentation is ... Eastern Time. , During the conference, the company will ...
... Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it ... Monday, November 9, 2009, following the close of the U.S. financial ... 5:00 p.m. Eastern Time on the same day to discuss these ... available for two weeks following the event. The conference call, ...
Cached Medicine Technology:Quest Diagnostics To Speak At The Oppenheimer 20th Annual Healthcare Conference 2Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 2Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 3
(Date:9/3/2015)... ... September 03, 2015 , ... William Mattar Law Offices is ... believes this does not stop at any certain demographic or segment of the population. ... one-minute, thirty-, fifteen- and ten-second TV commercials. , The closed captioning will allow people ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ... and Indiana University, Indianapolis, have chosen Center for Hospice Care (CHC) for ... institutions will train at CHC as part of fulfilling their requirements for obtaining ...
(Date:9/3/2015)... ... September 03, 2015 , ... Results of a comprehensive ... Research and Policy Analysis has found physician leadership development training programs to be ... of respondents said their organizations conduct some kind of physician leadership development program, ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... Florida Companies to Watch for 2015 by economic development group GrowFL ... only 50 companies in the state selected for this prestigious award, which recognizes ...
(Date:9/3/2015)... ... September 03, 2015 , ... Advice columnist, professional life ... debut book, “Stop Wasting Your Time Blaming Others for Your Life.” , Released ... to overcoming life’s obstacles by taking full responsibility for one’s life shares 15 ...
Breaking Medicine News(10 mins):Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:Survey finds growing movement for physician leadership training 2Health News:Survey finds growing movement for physician leadership training 3Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 3Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3
... artemisinin-based combination therapies to prevent malaria //parasites from developing ... the National Agency for Food and Drug Administration and ... the parasite already has grown resistant to chloroquine and ... be difficult to find another malaria treatment. ...
... Court has issued notices to the state government and Delhi ... teacher at its Doha branch claiming Rs 1.5 million for ... after preliminary arguments on former teacher Vibha Kapur's plea, Justice ... chairman to file their replies by April 3. ...
... Hopkins Scleroderma Center together with engineers from the university's ... monitor that// checks a patient's finger for symptoms of ... device seem to be promising: ,The Ambulatory ... secured with a bandage or medical tape. It contains ...
... The U.S. Food and Drug Administration (FDA) today ... Complex (Human), Alphanate. //The product is approved for ... Willebrand disease (vWD) in whom the hormone desmopressin ... approved for patients with severe vWD (Type 3) ...
... All India Institute of Medical Sciences (AIIMS) director P. ... public relation officer filed a police complaint against him. ... relation officer of AIIMS, has filed a police complaint ... accusing Venugopal of harassment, wrongful restraint from entering office, ...
... British scientists have developed a house to help people with ... a warning when it thinks there may be a problem. ... Institute of Medical Engineering could mean elderly people with fading ... rather than being forced to go into care homes, reported ...
Cached Medicine News:Health News:Ex-teacher Sues Delhi Public School 2Health News:Space-Age Bandage Monitors Patients With Raynaud's Disease 2Health News:FDA Approves New Product to Treat Von Willebrand Disease 2Health News:AIIMS Official Files Complaint Against Venugopal 2Health News:‘Smart House’ Developed to Monitor People With Dement 2
Farabeuf periosteal elevators....
OHL periosteal elevator, 19 cm, 7-1/2"....
Steinhauser periosteal elevator....
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Medicine Products: